TherapeuticsMD, Inc.

NasdaqGS:TXMD Lagerbericht

Marktkapitalisierung: US$24.5m

TherapeuticsMD Management

Management Kriterienprüfungen 3/4

Wir verfügen derzeit nicht über ausreichende Informationen über den CEO.

Wichtige Informationen

Marlan Walker

Geschäftsführender

US$561.1k

Gesamtvergütung

Prozentsatz des Geschäftsführergehalts89.10%
Amtszeit als Geschäftsführer3.4yrs
Eigentum des Geschäftsführers1.2%
Durchschnittliche Amtszeit des Managementskeine Daten
Durchschnittliche Amtszeit der Vorstandsmitglieder10.1yrs

Jüngste Management Updates

Recent updates

Seeking Alpha • Oct 03

TherapeuticsMD raises $7M in private placement

TherapeuticsMD (NASDAQ:TXMD) has received a $7M private investment in the Company’s Series A Preferred Stock from Rubric Capital Management LP. TherapeuticsMD expects to use the proceeds from the transaction for working capital. Under the terms of the Company’s financing agreement with its lender, Sixth Street Specialty Lending, upon receipt of the investment and the delivery to Sixth Street of warrants to acquire 125,000 shares of the Company’s common stock at an exercise price of $0.01 per share, the maturity date of the financing agreement was automatically extended until October 31, 2022. The Company has the option to further extend the maturity date until November 30, 2022, if it receives additional equity capital of $7 million. Source: Press Release
Seeking Alpha • Sep 12

TherapeuticsMD appoints interim co-CEOs

TherapeuticsMD (NASDAQ:TXMD) appointed Brian Bernick and Mark Glickman as interim co-CEO and co-principal executive officers. Bernick and Glickman succeed Hugh O’Dowd as CEO, the company said in a Sept. 12 press release. Prior to this appointment, Bernick, the company's co-founder, served as chief scientific and medical officer, and Glickman served as chief business officer. TherapeuticsMD also appointed Tommy Thompson, who served as chairman since 2012, as the executive chairman of the Board.
Seeking Alpha • Aug 12

Therapeutics MD Q2 Earnings Preview

Therapeutics MD (NASDAQ:TXMD) is scheduled to announce Q2 earnings results on Monday, August 15th, before market open. The consensus EPS Estimate is -$3.04 (-2663.6% Y/Y) and the consensus Revenue Estimate is $23.2M (+0.9% Y/Y). Over the last 1 year, TXMD has beaten EPS estimates 25% of the time and has beaten revenue estimates 100% of the time. Over the last 3 months, EPS estimates have seen 0 upward revision and 0 downward. Revenue estimates have seen 0 upward revision and 1 downward.
Seeking Alpha • Aug 01

TherapeuticsMD receives $15M equity investment from Rubric Capital

TherapeuticsMD (NASDAQ:TXMD) received a $15M private investment in its common stock and a new series of preferred stock PIPE from Rubric Capital Management. Proceeds to be used for fulfilling its near-term operating capital requirements. In exchange for its initial $15M investment, Rubric received 565K shares of TherapeuticsMD common stock and 15K shares of newly designated Series A Preferred Stock, with a liquidation value of $1,333/share. Post transaction closure, Rubric will own ~18.3% of stock. The company also entered into an amendment with its lender, Sixth Street Specialty Lending, to extend the maturity date of of its financing agreement debt to Sep.30, 2022. The company also granted Sixth Street warrants to acquire 200K shares at an exercise price of $0.01 and would grant 125K additional common stock warrants for each additional monthly extension. It also has the option to further extend the maturity date until Oct. 31, 2022 and Nov. 30, 2022 if it receives additional equity capital of $7M per extension.
Seeking Alpha • Jul 19

TherapeuticsMD jumps 12% as top investor discloses insider purchase

The shares of the women’s healthcare company TherapeuticsMD (NASDAQ:TXMD) surged ~12% on Tuesday after one of its leading institutional holders, Rubric Capital Management, announced the purchase of approximately 82.6K of company shares. The hedge fund, which had over 10% of company ownership, bought the shares on Friday and Monday at $5.56 and $6.03 apiece. The transactions valued at $467.4K have increased its holding by ~4%. Tuesday’s disclosure on the insider transactions comes days after TherapeuticsMD (TXMD) terminated its merger agreement with Athene Merger, an affiliate of EW Healthcare Partners. The deal fell apart after Athene failed to acquire the required number of TXMD shares during the tender offer, which the private equity firm previously extended, noting that TherapeuticsMD (TXMD) risked bankruptcy without the closure of the deal.
Seeking Alpha • Jul 13

TherapeuticsMD plunges 42% as merger agreement ends

The shares of TherapeuticsMD (NASDAQ:TXMD) dropped ~42% in the pre-market Wednesday after the women’s healthcare company announced the termination of its merger agreement with an Athene Merger, an affiliate of the private equity firm EW Healthcare Partners. The termination of the deal comes after Athene failed to acquire the required number of TXMD shares during an extended period of tender offer that ended on July 12. The end of the merger agreement is expected to take effect from July 13. Announcing the extension of the tender offer, EW Healthcare said last week that TherapeuticsMD (TXMD) risks bankruptcy without the closure of the merger deal. As of July 05, more than 2.5M TXMD shares or about ~29% of the company’s issued and outstanding shares, had been tendered.
Seeking Alpha • Jul 06

TherapeuticsMD risks bankruptcy as EW Healthcare extends tender offer for acquisition

Private equity firm EW Healthcare Partners announced on Wednesday that its affiliate Athene Merger extended the tender offer to acquire the women’s healthcare company TherapeuticsMD (NASDAQ:TXMD). Without a successful closure of the transaction, TherapeuticsMD (TXMD) will likely need to file for protection under Chapter 11, EW Healthcare reiterated. Per the revised terms, Athene Merger has extended the expiration date of its tender offer to July 12, 2022. As of July 05, more than 2.5M shares of TXMD, about ~29% of the issued and outstanding shares, had been tendered following the buyout offer. In May, TherapeuticsMD (TXMD) agreed to be acquired by an affiliate of EW Healthcare for $10 per share in an all-cash transaction. Previously, the parties expected to close the transaction before July 13.
Seeking Alpha • Jun 16

TherapeuticsMD: Privatization Deal Expected To Meet With Shareholder Pushback

TherapeuticsMD’s $177 million buyout deal with EW Healthcare largely undervalues the biotech. TherapeuticsMD is close to stimulating the commercialization of Annovera which may increase its value as a standalone company in the long run. Shareholders were informed of a 50:1 reverse stock split at the end of Q1 2021 just a few days before the buyout was announced. Investors are in support of the acquisition due to TherapeuticsMD's poor financial position but insist on better terms including an expanded bidding process.
Seeking Alpha • Mar 14

TherapeuticsMD: Looking For A Potential Turnaround After Divesting VitaCare Business

TherapeuticsMD had a rough 2021, and the share price shows it. The company battled the COVID-19 headwinds and has struggled to expand ANNOVERA’s manufacturing. TherapeuticsMD has an imposing product portfolio. Sadly, the company’s products have struggled to gain traction on the market, and the earnings show it. TherapeuticsMD is selling their vitaCare prescription health business to GoodRx for $150M in cash, with an extra $7M in contingent. The company can pay off some of their debt. I believe there is a chance we finally see a turnaround for TXMD. I discuss my plan for managing my position. I have the buy target at $0.35 with Sell 1 at $0.67 and Sell 2 at $1.49. I do have a Sell 3 at $2.14, however, I am probably going to have to adjust that in the coming weeks as the chart’s technicals change.
Seeking Alpha • Oct 22

TherapeuticsMD: Time For Bulls To Take A Contrarian Approach

Despite having an impressive product portfolio and established commercial organization, the company has struggled to get their products off the launchpad and through COVID-19 headwinds. Earnings have been lackluster while the cash burn continues to incinerate their cash position. Accordingly, the share price has been pummeled to all-time lows along with investor sentiment. I still have a long-term bullish outlook in anticipation the company is able to weather the COVID-19 headwinds and record significant growth in the coming years. I reveal my strategy for changing my position from a dark red to a bright green.
Seeking Alpha • Jul 08

TherapeuticsMD: The Long Road To Profitability

Although the market did not take favorably to recent Q1 numbers, there were some encouraging trends. ANNOVERA continues to execute as marketing strategies continue to build awareness. Costs came down significantly in Q1 and sales grew by over 60%. We need more of the same going forward.
Analyseartikel • Feb 24

TherapeuticsMD, Inc. (NASDAQ:TXMD): Are Analysts Optimistic?

TherapeuticsMD, Inc. ( NASDAQ:TXMD ) is possibly approaching a major achievement in its business, so we would like to...
Analyseartikel • Jan 29

TherapeuticsMD, Inc. (NASDAQ:TXMD) Analysts Are More Bearish Than They Used To Be

The analysts covering TherapeuticsMD, Inc. ( NASDAQ:TXMD ) delivered a dose of negativity to shareholders today, by...
Analyseartikel • Jan 27

What Type Of Shareholders Make Up TherapeuticsMD, Inc.'s (NASDAQ:TXMD) Share Registry?

Every investor in TherapeuticsMD, Inc. ( NASDAQ:TXMD ) should be aware of the most powerful shareholder groups...
Analyseartikel • Dec 30

Have Insiders Been Buying TherapeuticsMD, Inc. (NASDAQ:TXMD) Shares?

We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
Analyseartikel • Dec 09

TherapeuticsMD (NASDAQ:TXMD) Share Prices Have Dropped 87% In The Last Five Years

Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We really hate to see...

Analyse der Geschäftsführervergütung

Wie hat sich die Vergütung von Marlan Walker im Vergleich zu den Einnahmen von TherapeuticsMD verändert?
DatumGesamtvergütungGehaltUnternehmensgewinne
Mar 31 2026n/an/a

US$86k

Dec 31 2025US$561kUS$500k

-US$653k

Sep 30 2025n/an/a

US$73k

Jun 30 2025n/an/a

-US$544k

Mar 31 2025n/an/a

-US$2m

Dec 31 2024US$759kUS$500k

-US$2m

Sep 30 2024n/an/a

-US$4m

Jun 30 2024n/an/a

-US$5m

Mar 31 2024n/an/a

-US$6m

Dec 31 2023US$1mUS$476k

-US$8m

Sep 30 2023n/an/a

US$42m

Jun 30 2023n/an/a

US$29m

Mar 31 2023n/an/a

US$17m

Dec 31 2022US$2mUS$425k

US$1m

Sep 30 2022n/an/a

US$3m

Jun 30 2022n/an/a

-US$30m

Mar 31 2022n/an/a

-US$58m

Dec 31 2021US$2mUS$415k

-US$79m

Vergütung im Vergleich zum Markt: MarlanDie Gesamtvergütung ($USD561.14K) liegt im Durchschnitt der Unternehmen ähnlicher Größe auf dem Markt US ($USD624.15K).

Entschädigung vs. Einkommen: MarlanDie Vergütung des Vorstandsvorsitzenden entsprach im vergangenen Jahr der Unternehmensleistung.

Geschäftsführer

Marlan Walker (49 yo)

3.4yrs
Amtszeit
US$561,137
Vergütung

Mr. Marlan D. Walker, J.D., has been Chief Executive Officer of TherapeuticsMD, Inc since December 2022 and was its General Counsel since March 2016 until 2023. He served as the Secretary of TherapeuticsMD...

Vorstandsmitglieder

NamePositionAmtszeitVergütungEigentümerschaft
Gail Naughton
Independent Director6.2yrsUS$87.28k0.073%
$ 18.0k
Thomas Thompson
Independent Chairman of the Board14yrsUS$104.78k0.32%
$ 79.5k
Cooper Collins
Independent Director14.3yrsUS$109.28k0.52%
$ 128.3k
Justin Roberts
Independent Director3.8yrskeine Datenkeine Daten
10.1yrs
Durchschnittliche Betriebszugehörigkeit
57.5yo
Durchschnittliches Alter

Erfahrener Vorstand: TXMDDie Vorstandsmitglieder sind sehr erfahren ( 10.1 ).

Unternehmensanalyse und Finanzdaten Status

DatenZuletzt aktualisiert (UTC-Zeit)
Unternehmensanalyse2026/05/26 16:14
Aktienkurs zum Tagesende2026/05/26 00:00
Gewinne2026/03/31
Jährliche Einnahmen2025/12/31

Datenquellen

Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.

PaketDatenZeitrahmenBeispiel US-Quelle *
Finanzdaten des Unternehmens10 Jahre
  • Gewinn- und Verlustrechnung
  • Kapitalflussrechnung
  • Bilanz
Konsensschätzungen der Analysten+3 Jahre
  • Finanzielle Vorausschau
  • Kursziele der Analysten
Marktpreise30 Jahre
  • Aktienkurse
  • Dividenden, Splits und Aktionen
Eigentümerschaft10 Jahre
  • Top-Aktionäre
  • Insiderhandel
Verwaltung10 Jahre
  • Das Führungsteam
  • Direktorium
Wichtige Entwicklungen10 Jahre
  • Ankündigungen des Unternehmens

* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.

Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.

Analysemodell und Schneeflocke

Einzelheiten zu dem Analysemodell, mit dem dieser Bericht erstellt wurde, finden Sie auf unserer Github-Seite. Außerdem bieten wir Leitfäden zur Verwendung unserer Berichte und Tutorials auf YouTube an.

Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.

Metriken für Industrie und Sektor

Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.

Analysten-Quellen

TherapeuticsMD, Inc. wird von 17 Analysten beobachtet. 0 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.

AnalystEinrichtung
John TannerCantor Fitzgerald & Co.
Oren LivnatCitizens JMP Securities, LLC
Robert LabickCJS Securities, Inc.